Cushing´s Disease Epidemiology in Sweden
30. april 2019 oppdatert av: Vastra Gotaland Region
National Swedish Study in Cushing´s Disease Incidence and Outcomes
The purpose of this study is to study since 1987 all patients diagnosed with CD in Sweden and determine their outcomes including mortality.
A secondary objective is to focus on patients in remission and identify determinants of their different outcomes.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
This study is a retrospective nationwide study of all patients in Sweden with diagnosis CD between 1987 and 2013 were baseline data at diagnosis, information about the different treatments and follow-up data is going to be obtained by reviewing patients' medical journals. This information as well as the exact diagnose criteria for each patient are going to be extracted by Endocrinologists in all University Hospitals in Sweden. An expert group at the Sahlgrenska University Hospital in Gothenburg will put together the data.By the use of the Swedish Personal Number, the investigators are going to obtain information about both patients' and background population co-morbidities which have been collected in the different Swedish Registers.
Primary aim:
To study mortality of CD in Sweden.
Secondary aims:
- To study the influence of CD on myocardial infarction
- To study the influence of CD on stroke
- To study the influence of CD on cancer
- To study the influence of CD on hip fracture risk
- To study incidence and prevalence of CD in Sweden.
Studietype
Observasjonsmessig
Registrering (Faktiske)
502
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Vastra Gotaland Region
-
Gothenburg, Vastra Gotaland Region, Sverige, 413 45
- Sahlgrenska University Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
All adult patients with confirmed CD diagnosis in Sweden
Beskrivelse
Inclusion Criteria:
- All patients registered with Cushing's Disease in Sweden since 1987 in the statistical database for in- and out-patients, at the Swedish National Board of Health and Welfare will be included in the study.
Exclusion Criteria:
- No
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Patients with verified Cushing's Disease
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mortality
Tidsramme: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years.
|
If event (death) has been occured during the observation period.
Data obtained by the Swedish Cause Of Death Register (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
influence of Cushing's Disease on myocardial infarction
Tidsramme: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (myocardial infarction) has been occured during the observation period.Data obtained by the Swedish Register of In- and Out-patient Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
influence of Cushing's Disease on stroke
Tidsramme: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (stroke) has been occured during the observation period.Data obtained by the Swedish Register of In- and Out-patient Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
influence of Cushing's Disease on cancer
Tidsramme: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (cancer) has been occured during the observation period.Data obtained by the Swedish Register of Cancer Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
influence of Cushing's Disease on hip fracture risk
Tidsramme: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (hip fracture) has been occured during the observation period.Data obtained by the Swedish Register of Hip Fractures (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
incidence of Cushing's Disease in Sweden
Tidsramme: Assessed up to 20 years.
|
Validation of Data obtained by The Swedish Board of Health and Welfare by reviewing all patients' journals
|
Assessed up to 20 years.
|
|
prevalence of Cushing's Disease in Sweden
Tidsramme: Assessed up to 20 years.
|
Validation of Data obtained by The Swedish Board of Health and Welfare by reviewing all patients' journals
|
Assessed up to 20 years.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Gudmundur Johannsson, Professor, Vastra Gotaland Region, Sahlgrenska University Hospital
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. september 2013
Primær fullføring (Faktiske)
1. april 2019
Studiet fullført (Faktiske)
1. april 2019
Datoer for studieregistrering
Først innsendt
5. desember 2014
Først innsendt som oppfylte QC-kriteriene
23. januar 2015
Først lagt ut (Anslag)
29. januar 2015
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
3. mai 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
30. april 2019
Sist bekreftet
1. april 2019
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer, kjertel og epitel
- Sykdommer i det endokrine systemet
- Neoplasmer i endokrine kjertel
- Hypothalamiske sykdommer
- Hyperpituitarisme
- Hypofyse sykdommer
- Adenom
- Hypofyse neoplasmer
- ACTH-utskillende hypofyseadenom
- Hypofyse ACTH Hypersekresjon
Andre studie-ID-numre
- NSSCDIO
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .